Valneva's (VALN) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• Valneva's stock rating has been reiterated as a "sell (D-)" by Weiss Ratings, highlighting ongoing concerns among analysts.
• Despite the sell rating, three other analysts rate Valneva as a "buy", with an average price target of $15.00.
• Valneva's recent earnings report showed it beat expectations with a revenue of $54.84 million, although it also reported a negative return on equity of 34.78%.

Valneva (NASDAQ:VALN - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities research analysts at Weiss Ratings in a report issued on Friday,Weiss Ratings reports.

Other equities analysts have also recently issued research reports about the company. HC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Valneva in a report on Monday, August 25th. Guggenheim cut their price objective on shares of Valneva from $14.00 to $13.00 and set a "buy" rating for the company in a research report on Monday, September 8th. Jefferies Financial Group set a $14.00 price objective on shares of Valneva and gave the stock a "buy" rating in a research report on Monday, August 25th. Finally, Wall Street Zen raised shares of Valneva to a "hold" rating in a report on Saturday, September 6th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $15.00.

Valneva Trading Down 1.3%

VALN stock traded down $0.13 during trading hours on Friday, reaching $9.55. 42,808 shares of the stock were exchanged, compared to its average volume of 66,055. The firm's 50-day moving average is $10.07 and its 200-day moving average is $7.82. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.27 and a quick ratio of 1.77. Valneva has a 12 month low of $3.62 and a 12 month high of $12.25.

Valneva (NASDAQ:VALN - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.11. The firm had revenue of $54.84 million during the quarter, compared to analysts' expectations of $46.28 million. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%. As a group, sell-side analysts anticipate that Valneva will post 0.13 EPS for the current year.

Institutional Trading of Valneva

A hedge fund recently bought a new stake in Valneva stock. Marex Group plc bought a new position in shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 11,300 shares of the company's stock, valued at approximately $64,000. 11.39% of the stock is currently owned by institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.